New combo therapy shows promise for rare blood cancer
Disease control
Not yet recruiting
This study tests two drugs, tislelizumab and zeprumetostat, together in people with NK/T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if the combination can shrink tumors and to find the safest dose. About 107 adults will take part, and…
Phase: PHASE1, PHASE2 • Sponsor: Rong Tao • Aim: Disease control
Last updated May 12, 2026 13:40 UTC